"False"
Umeå universitet
printicon
Huvudmenyn dold.

Erik Håkansson

0000-0003-1545-178X

Kontakt

E-post
erik.hakansson@umu.se

Verksam som

Anknytning
Doktorand vid Institutionen för folkhälsa och klinisk medicin
Plats
Byggnad 1A, plan 4, målpunkt B41, Norrlands universitetssjukhus Umeå universitet, 901 85 Umeå SE
Sodium-glucose cotransporter 2 inhibitors in heart failure and transthyretin cardiac amyloidosis
Umeå University medical dissertations
Håkansson, Erik
Assessment of a systematic approach for implementing novel medications in clinical practice: an observational study with dapagliflozin
European Journal of Clinical Pharmacology, Springer Nature 2024, Vol. 80, (9) : 1363-1371
Norberg, Helena; Andersson, Therese; Håkansson, Erik; et al.
Prevalence and treatment of diabetes and pre-diabetes in a real-world heart failure population: a single-centre cross-sectional study
Open heart, BMJ Publishing Group Ltd 2022, Vol. 9, (2)
Håkansson, Erik; Brunström, Mattias; Norberg, Helena; et al.
Eligibility of Dapagliflozin and Empagliflozin in a Real-World Heart Failure Population
Cardiovascular Therapeutics, Hindawi Publishing Corporation 2021, Vol. 2021
Håkansson, Erik; Norberg, Helena; Själander, Sara; et al.
Using dapagliflozin to reduce symptoms in transthyretin cardiac amyloidosis: a n-of-1 trial series pilot study
Håkansson, Erik; Anan, Intissar; Brunström, Mattias; et al.
Design and rationale of the ULRICA trial: using dapagliflozin to reduce symptoms and improve walking distance in transthyretin cardiac amyloidosis
Håkansson, Erik; Pilebro, Björn; Lindmark, Krister
Visa publikationer i DiVA